Home/Pipeline/DE-130 (EYP-1901)

DE-130 (EYP-1901)

Wet AMD

Phase 3In-licensed (EyePoint), Planned

Key Facts

Indication

Wet AMD

Phase

Phase 3

Status

In-licensed (EyePoint), Planned

Company

Santen

About Santen

Santen Pharmaceutical Co., Ltd. is a leading global ophthalmology company founded in 1890 with a mission to achieve 'Happiness with Vision.' The company has built a fully integrated business model spanning R&D, manufacturing, and commercialization, serving patients in over 60 countries. Its strategy is centered on deepening its ophthalmic expertise, expanding its portfolio through internal innovation and strategic partnerships, and aiming to become the most trusted global ophthalmology company by 2035.

View full company profile

Therapeutic Areas

Ophthalmology Glaucoma Retinal Diseases Ocular Inflammation Dry Eye Disease Ocular Allergy

Other Wet AMD Drugs

Drug	Company	Phase	Status
PST-809	PulseSight Therapeutics	Phase 1/2	Active